1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4.
Voice of Customer
5.
Global Cellular
Immunotherapy Market Outlook
5.1. Market Size & Forecast
5.1.1.
By Value
5.2. Market Share & Forecast
5.2.1.
By Therapy Type (CAR T Cell Therapy, Dendritic Cell
Therapy, NK Cell Therapy, TIL Therapy, Others)
5.2.2.
By Indication
(B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma,
Others)
5.2.3.
By
End-Use (Hospitals, Cancer Institutes, Others)
5.2.4. By
Region (North America, Europe, Asia Pacific, South America, Middle East &
Africa)
5.2.5. By
Company (2022)
5.3. Market Map
5.3.1
By Therapy Type
5.3.2 By Indication
5.3.3
By End-Use
5.3.4 By Region
6.
North America
Cellular Immunotherapy Market Outlook
6.1. Market Size & Forecast
6.1.1.
By Value
6.2. Market Share & Forecast
6.2.1. By
Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL
Therapy,
Others)
6.2.2.
By
Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell
Carcinoma, Others)
6.2.3.
By
End-Use (Hospitals, Cancer Institutes, Others)
6.2.4.
By Country
6.3. North America: Country Analysis
6.3.1.
United States
Cellular Immunotherapy Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Therapy Type
6.3.1.2.2.
By Indication
6.3.1.2.3.
By End-Use
6.3.2.
Canada Cellular
Immunotherapy Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Therapy Type
6.3.2.2.2.
By Indication
6.3.2.2.3.
By End-Use
6.3.3.
Mexico Cellular
Immunotherapy Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Therapy Type
6.3.3.2.2.
By Indication
6.3.3.2.3.
By End-Use
7.
Europe Cellular
Immunotherapy Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1.
By Therapy Type (CAR T Cell Therapy, Dendritic Cell
Therapy, NK Cell Therapy, TIL Therapy, Others)
7.2.2.
By
Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell
Carcinoma, Others)
7.2.3.
By
End-Use (Hospitals, Cancer Institutes, Others)
7.2.4.
By Country
7.3. Europe: Country Analysis
7.3.1.
France Cellular
Immunotherapy Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Therapy Type
7.3.1.2.2.
By Indication
7.3.1.2.3.
By End-Use
7.3.2.
Germany Cellular
Immunotherapy Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Therapy Type
7.3.2.2.2.
By Indication
7.3.2.2.3.
By End-Use
7.3.3.
United Kingdom
Cellular Immunotherapy Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Therapy Type
7.3.3.2.2.
By Indication
7.3.3.2.3.
By End-Use
7.3.4.
Italy Cellular
Immunotherapy Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Therapy Type
7.3.4.2.2.
By Indication
7.3.4.2.3.
By End-Use
7.3.5.
Spain Cellular
Immunotherapy Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Therapy Type
7.3.5.2.2.
By Indication
7.3.5.2.3.
By End-Use
8.
Asia-Pacific
Cellular Immunotherapy Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Therapy Type (CAR T Cell Therapy, Dendritic Cell
Therapy, NK Cell Therapy, TIL Therapy, Others)
8.2.2.
By
Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell
Carcinoma, Others)
8.2.3.
By
End-Use (Hospitals, Cancer Institutes, Others)
8.2.4.
By Country
8.3. Asia-Pacific: Country Analysis
8.3.1.
China Cellular
Immunotherapy Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Therapy Type
8.3.1.2.2.
By Indication
8.3.1.2.3.
By End-Use
8.3.2.
India Cellular
Immunotherapy Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Therapy Type
8.3.2.2.2.
By Indication
8.3.2.2.3.
By End-Use
8.3.3.
Japan Cellular Immunotherapy
Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Therapy Type
8.3.3.2.2.
By Indication
8.3.3.2.3.
By End-Use
8.3.4.
South Korea Cellular
Immunotherapy Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Therapy Type
8.3.4.2.2.
By Indication
8.3.4.2.3.
By End-Use
8.3.5.
Australia Cellular
Immunotherapy Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Therapy Type
8.3.5.2.2.
By Indication
8.3.5.2.3.
By End-Use
9.
South America
Cellular Immunotherapy Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Therapy Type (CAR T Cell Therapy, Dendritic Cell
Therapy, NK Cell Therapy, TIL Therapy, Others)
9.2.2.
By
Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell
Carcinoma, Others)
9.2.3.
By
End-Use (Hospitals, Cancer Institutes, Others)
9.2.4.
By Country
9.3. South America: Country Analysis
9.3.1.
Brazil Cellular
Immunotherapy Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Therapy Type
9.3.1.2.2.
By Indication
9.3.1.2.3.
By End-Use
9.3.2.
Argentina Cellular Immunotherapy
Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Therapy Type
9.3.2.2.2.
By Indication
9.3.2.2.3.
By End-Use
9.3.3.
Colombia Cellular
Immunotherapy Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Therapy Type
9.3.3.2.2.
By Indication
9.3.3.2.3.
By End-Use
10.
Middle East and
Africa Cellular Immunotherapy Market Outlook
10.1.
Market Size &
Forecast
10.1.1.
By Value
10.2.
Market Share &
Forecast
10.2.1.
By Therapy Type (CAR T Cell Therapy, Dendritic Cell
Therapy, NK Cell Therapy, TIL Therapy, Others)
10.2.2.
By Indication
(B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma,
Others)
10.2.3.
By
End-Use (Hospitals, Cancer Institutes, Others)
10.2.4.
By Country
10.3.
MEA: Country
Analysis
10.3.1.
South Africa
Cellular Immunotherapy Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Therapy Type
10.3.1.2.2.
By Indication
10.3.1.2.3.
By End-Use
10.3.2.
Saudi Arabia
Cellular Immunotherapy Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Therapy Type
10.3.2.2.2.
By Indication
10.3.2.2.3.
By End-Use
10.3.3.
UAE Cellular Immunotherapy
Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Therapy Type
10.3.3.2.2.
By Indication
10.3.3.2.3.
By End-Use
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Development
12.2.
Mergers &
Acquisitions
12.3.
Product Launches
13.
Global Cellular Immunotherapy Market: SWOT Analysis
14.
Porter’s Five Forces Analysis
14.1.
Competition in the
Industry
14.2.
Potential of New
Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute
Products
15. Competitive Landscape
15.1.
Bristol-Myers Squibb
Company.
15.1.1.
Business Overview
15.1.2.
Product Offerings
15.1.3.
Recent Developments
15.1.4.
Financials (As
Reported)
15.1.5.
Key Personnel
15.1.6.
SWOT Analysis
15.2.
Novartis AG.
15.3.
Gilead Sciences Inc.
(Kite Pharma)
15.4.
F. Hoffmann-La Roche
Ltd.
15.5.
Merck KGaA.
15.6.
GlaxoSmithKline plc.
15.7.
AstraZeneca Plc.
15.8.
Pfizer Inc.
15.9.
Johnson &
Johnson.
15.10.
Celyad.
16. Strategic Recommendations